IMVT
VENTE TOTALE: 3 000 titres (~124 605,00 $ US)
- Insiders
- Pande Atul
- Total bought
- —
- Total sold
- $124,605
- Last activity
- 2026-08-28
- Last synced
-
2026-09-03 09:53:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-02
IMVT presents a deeply unfavorable risk/reward profile: despite adequate near-term liquidity (score 85), the fundamentals trend is critically weak (score 15) with zero revenue, persistent cash burn, and declining…
The first sentence of the analysis written for IMVT on 2026-09-02 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.086 | 11.162 | 13.697 | 9.339 | 11.521 | |
| Quick Ratio | 9.086 | 11.162 | 13.697 | 9.339 | 11.521 | |
| Solvency Ratio | -4.813 | -6.012 | -5.293 | -4.863 | -3.424 | |
| Cash Ratio | 8.639 | 10.381 | 13.071 | 8.696 | 11.092 | |
| Price To Earnings Ratio | -8.968 | -6.260 | -16.814 | -9.070 | -3.853 | |
| Price To Earnings Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Forward Price To Earnings Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Price To Earnings Diluted Ratio | -8.968 | -6.260 | -16.814 | -9.070 | -3.853 | |
| Price To Earnings Diluted Growth Ratio | -6.120 | -0.138 | -1.691 | -0.463 | -0.224 | |
| Price To Book Ratio | 5.315 | 3.662 | 7.066 | 5.266 | 1.286 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -11.125 | -6.878 | -20.343 | -10.133 | -5.682 | |
| Price To Operating Cash Flow Ratio | -11.125 | -6.892 | -20.377 | -10.143 | -5.695 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.003 | 0.005 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.123 | 1.097 | 1.079 | 1.120 | 1.097 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.901 | -5.465 | -4.407 | -4.347 | -2.383 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.002 | 1.002 | 1.001 | 1.002 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -15.886 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -16.686 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5,657.083 | -3,835.449 | -1,552.370 | -154.257 | -44.887 | |
| Capital Expenditure Coverage Ratio | -50,913.750 | -495.223 | -595.075 | -955.294 | -417.764 | |
| Dividend Paid And Capex Coverage Ratio | -50,913.750 | -495.223 | -595.075 | -955.294 | -417.764 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.187 | -4.548 | -14.428 | -7.735 | -0.720 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 9.086 | ▼-2.075 | ▼-1.875 |
| Quick Ratio | 9.086 | ▼-2.075 | ▼-1.875 |
| Solvency Ratio | -4.812 | ▲1.199 | ▲0.068 |
| Cash Ratio | 8.639 | ▼-1.742 | ▼-1.737 |
| Price To Earnings Ratio | -8.967 | ▼-2.707 | ▲0.025 |
| Price To Earnings Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Forward Price To Earnings Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Price To Earnings Diluted Ratio | -8.967 | ▼-2.707 | ▲0.025 |
| Price To Earnings Diluted Growth Ratio | -6.120 | ▼-5.982 | ▼-4.393 |
| Price To Book Ratio | 5.315 | ▲1.653 | ▲0.796 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -11.125 | ▼-4.247 | ▼-0.293 |
| Price To Operating Cash Flow Ratio | -11.125 | ▼-4.233 | ▼-0.279 |
| Debt To Assets Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Debt To Equity Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Debt To Capital Ratio | 0.000 | ▼-0.000 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.123 | ▲0.026 | ▲0.020 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3.901 | ▲1.565 | ▲0.200 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.002 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲3.177 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲3.337 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -5657.083 | ▼-1821.634 | ▼-3408.274 |
| Capital Expenditure Coverage Ratio | -50913.750 | ▼-50418.527 | ▼-40238.329 |
| Dividend Paid And Capex Coverage Ratio | -50913.750 | ▼-50418.527 | ▼-40238.329 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.187 | ▼-2.639 | ▼-0.263 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $4.53B | $2.59B | $4.37B | $1.91B | $604.3M | |
| Enterprise value | $3.63B | $1.88B | $3.73B | $1.53B | $112.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -8.91x | -4.99x | -17.41x | -8.15x | -1.06x | |
| EV / Free cash flow | -8.91x | -4.98x | -17.38x | -8.14x | -1.06x | |
| EV / EBITDA | -7.19x | -4.55x | -14.43x | -7.74x | -0.72x | |
| Net debt / EBITDA | 1.79x | 1.73x | 2.46x | 1.89x | 3.14x | |
| Current ratio | 9.09x | 11.16x | 13.70x | 9.34x | 11.52x | |
| Income quality | 0.81x | 0.91x | 0.83x | 0.89x | 0.68x | |
| Graham net-net | $4 | $4 | $4 | $3 | $4 | |
| Tax burden | 100.0% | 100.2% | 100.2% | 100.0% | 99.9% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 106.3% | 100.0% | |
| Working capital | $844.4M | $698.9M | $617.2M | $361.0M | $468.4M | |
| Invested capital | $844.9M | $699.8M | $617.8M | $362.5M | $471.0M | |
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | |
| Operating ROA | -61.5% | -60.7% | -50.4% | -45.2% | -33.6% | |
| Return on tangible assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% | |
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% | |
| Return on invested capital | -62.5% | -61.9% | -43.7% | -57.3% | -33.0% | |
| Return on capital employed | -62.5% | -61.9% | -43.7% | -57.4% | -33.1% | |
| Earnings yield | -11.2% | -16.0% | -5.9% | -11.1% | -25.9% | |
| Free cash flow yield | -9.0% | -14.5% | -4.9% | -9.9% | -17.6% | |
| Capex / Op. cash flow | -0.0% | -0.2% | -0.2% | -0.1% | -0.2% | |
| Capex / Depreciation | 2.0% | 201.3% | 155.8% | 102.1% | 201.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 6730d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -6730d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+74.9%EV / Sales n/aEV / EBITDA ▼-58.0%EV / Op. cash flow ▼-3.918Earnings yield ▲+0.048
Profitability
Return on equity ▼-0.008Return on assets ▲+0.005Return on invested capital ▼-0.005Return on capital employed ▼-0.005Operating ROA ▼-0.007Income quality ▼-0.103Tax burden ▼-0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.076Net debt / EBITDA ▲+0.056Working capital ▲+145510000.000Invested capital ▲+145083000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+649.8%EV / Sales n/aEV / EBITDA ▼-897.6%EV / Op. cash flow ▼-7.847Earnings yield ▲+0.148
Profitability
Return on equity ▼-0.259Return on assets ▼-0.224Return on invested capital ▼-0.294Return on capital employed ▼-0.293Operating ROA ▼-0.278Income quality ▲+0.129Tax burden ▲+0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.435Net debt / EBITDA ▼-1.350Working capital ▲+375986000.000Invested capital ▲+373868000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-27 Algert Global LLC Raises Position in Immunovant, Inc. $IMVT Algert Global LLC increased its stake in Immunovant, Inc. (NASDAQ: IMVT) by 51.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 159,840 shares of the company''s stock after buying an additional 54,070 shares during the quarter. Algert Global LLC owned about
- 2026-08-19 Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 2026-08-18 Immunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy? Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $43.89 and last traded at $43.71, with a volume of 1216514 shares. The stock had previously closed at $41.82. Wall Street Analysts Forecast Growth A number of analysts recently
- 2026-08-06 Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
- 2026-08-06 Immunovant Q1 Earnings Call Highlights Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.
- 2026-08-06 Immunovant''s Q1 Loss Wider Than Expected, Pipeline in Progress IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves'' disease commercial launch.
- 2026-08-06 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves'' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren''s disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.
- 2026-07-27 Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402''s differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves'' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.
- 2026-07-20 Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
- 2026-06-19 Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? Immunovant (IMVT) reported earnings 30 days ago. What''s next for the stock?